NMTRQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NMTRQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, 9 Meters Biopharma's Enterprise Value is $0.00 Mil. 9 Meters Biopharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 was $-42.86 Mil. Therefore, 9 Meters Biopharma's EV-to-EBIT ratio for today is 0.00.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, 9 Meters Biopharma's Enterprise Value is $0.00 Mil. 9 Meters Biopharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 was $-42.86 Mil. Therefore, 9 Meters Biopharma's EV-to-EBITDA ratio for today is 0.00.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, 9 Meters Biopharma's Enterprise Value is $0.00 Mil. 9 Meters Biopharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2023 was $0.00 Mil. Therefore, 9 Meters Biopharma's EV-to-Revenue ratio for today is .
The historical data trend for 9 Meters Biopharma's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
9 Meters Biopharma Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Enterprise Value | Get a 7-Day Free Trial | 59.73 | 20.63 | 138.16 | 205.91 | 23.51 |
9 Meters Biopharma Quarterly Data | ||||||||||||||||||||
Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | |
Enterprise Value | Get a 7-Day Free Trial | 117.67 | 38.26 | 58.37 | 23.51 | 18.16 |
For the Biotechnology subindustry, 9 Meters Biopharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, 9 Meters Biopharma's Enterprise Value distribution charts can be found below:
* The bar in red indicates where 9 Meters Biopharma's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
9 Meters Biopharma's Enterprise Value for the fiscal year that ended in Dec. 2022 is calculated as
Enterprise Value (A: Dec. 2022 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 16.425864 | + | 0 | + | 0.051 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 19.678 | + | 0 | - | 12.646 |
= | 23.51 |
9 Meters Biopharma's Enterprise Value for the quarter that ended in Mar. 2023 is calculated as
Enterprise Value (Q: Mar. 2023 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 19.927596 | + | 0 | + | 0.035 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 5.135 | + | 0 | - | 6.939 |
= | 18.16 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
9 Meters Biopharma (OTCPK:NMTRQ) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
9 Meters Biopharma's EV-to-EBIT for today is
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 0.000 | / | -42.863 | |
= | 0.00 |
9 Meters Biopharma's current Enterprise Value is $0.00 Mil.
9 Meters Biopharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-42.86 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
9 Meters Biopharma's EV-to-EBITDA for today is:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA(TTM) |
= | 0.000 | / | -42.855 | |
= | 0.00 |
9 Meters Biopharma's current Enterprise Value is $0.00 Mil.
9 Meters Biopharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-42.86 Mil.
3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.
9 Meters Biopharma's EV-to-Revenue for today is:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 0.000 | / | 0 | |
= |
9 Meters Biopharma's current Enterprise Value is $0.00 Mil.
9 Meters Biopharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of 9 Meters Biopharma's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Bethany Sensenig | officer: Chief Financial Officer | C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615 |
John Temperato | director, officer: Chief Executive Officer | C/O MELINTA THERAPEUTICS,INC., 300 GEORGE STREET, SUITE 301, NEW HAVEN CT 06511 |
Mark A Sirgo | director | C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607 |
Michael T. Constantino | director | C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615 |
Samantha Ventimiglia | director | C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615 |
Edward J Sitar | officer: Chief Financial Officer | 39 FLAMING ARROW ROAD, MAHWAH NJ 07430 |
Orbimed Israel Biofund Gp Limited Partnership | 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629 |
Yehuda Michael Rice | director | 155 WALNUT STREET, ENGLEWOOD NJ 07631 |
Nissim Darvish | director, 10 percent owner | C/O INNOVATE BIOPHARMACEUTICALS, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615 |
Orbimed Israel Gp Ltd. | 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629 |
Sandeep Laumas | director, officer: Executive Chairman | 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615 |
Jay P. Madan | director, officer: President | 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615 |
Roy Proujansky | director | 144 PAU NEL DRIVE, LANDENBERG PA 19350 |
Christopher P. Prior | director, officer: Chief Executive Officer | 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615 |
June Sherie Almenoff | officer: COO and Chief Medical Officer | C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019 |
From GuruFocus
By ACCESSWIRE ACCESSWIRE • 01-31-2023
By ACCESSWIRE ACCESSWIRE • 03-02-2022
By ACCESSWIRE ACCESSWIRE • 06-14-2022
By ACCESSWIRE ACCESSWIRE • 11-14-2022
By ACCESSWIRE ACCESSWIRE • 08-15-2022
By ACCESSWIRE ACCESSWIRE • 05-16-2022
By ACCESSWIRE ACCESSWIRE • 06-21-2022
By ACCESSWIRE ACCESSWIRE • 03-01-2022
By ACCESSWIRE ACCESSWIRE • 09-01-2022
By ACCESSWIRE ACCESSWIRE • 03-28-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.